Ballicules.com

Guaifenesin

MUCINEX

Pronunciation: gwye-FEN-e-sin

Guaifenesin ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Guaifenesin ballicule
Guaifenesin MUCINEX mascot mnemonic cartoon
Visual mnemonic: Guaifenesin mascot
“Mucin, next Guy fencin’”

What it isExpectorant with incidental NMDA antagonism and an otherwise uncertain target; cough with thick secretions.

Why this oneIt is the only widely used oral expectorant, but its popularity greatly exceeds the strength of its evidence.

What limits itBenefit is often indistinguishable from hydration; stop if there is no clear response rather than escalating combination products.

Guaifenesin molecular structure (skeletal formula)
Molecular structure: Guaifenesin

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Expectorant (OTC Uses): helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productiveAdults and children >=12 y1-2 tablets (600-1,200 mg ER) q12h1-2 tablets (600-1,200 mg ER) q12h4 tablets (2,400 mg) per 24 h
Expectorant (OTC Uses): helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productiveChildren <12 yDo not useDo not useDo not use

Renal Undefined

Hepatic Undefined

Do not exceed 4 tablets in 24 hours.

Instructions

Available strengths

Pregnancy Undefined

Lactation Undefined

Cost

Guaifenesin (MUCINEX)
What pharmacies pay · NADAC 9/30/26 · OTC
Strength#/mogeneric $/moCostPlus
600 mgER tab60 BID$17.04out of stock
1200 mgER tab60 BID$25.90not offered

Generic entryPre-1982

NO BOXED WARNINGS

Principal riskLittle

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — OTC/monograph

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Guaifenesin in the interactive console ↗